clenbuterol

Phase 2Small molecule

UUniversity of Copenhagen

clenbuterol is one of 149 small molecule programs targeting Amyotrophic Lateral Sclerosis. It is currently in Phase 2.

Indications

Total Trials

Active Trials

148

Competitors

Pipeline

Status by Indication[3][1]

Indication

Amyotrophic Lateral SclerosisActive, not recruiting

AtrophyActive, not recruiting

MemoryActive, not recruiting

Heart FailureActive, not recruiting

Pompe DiseaseActive, not recruiting

Amyotrophic Lateral SclerosisPhase 2

Active, not recruiting

AtrophyPhase 2

Active, not recruiting

MemoryPreclinical

Active, not recruiting

Heart FailurePhase 1

Active, not recruiting

Pompe DiseasePhase 2

Active, not recruiting

Competition

Competitive Landscape

687 competitors in Heart Failure

#DrugCompanyPhaseTrials

clenbuterol

UUniversity of Copenhagen

Phase 2

1 2

Brethine

Sanofi

Preclinical

1 3

Amidate

Pfizer

Preclinical

1 4

Medrol

Pfizer

Preclinical

1 5

LCZ696

Novartis

Preclinical

15 6

Monoferric

PPharmacosmos A/S

Preclinical

5 7

Xifaxan

SSalix

Preclinical

2 8

Zoloft

VViatris Specialty LLC

Preclinical

2 9

Statin

Bristol-Myers Squibb

Preclinical

1 10

GLP-1

RRigshospitalet, Denmark

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Phase 2Recruiting

Atrophy

NCT06169046

Q3 2028

Phase 1Recruiting

FSHD

NCT06721299

Clinical

Trials by Indication[1]

Pompe Disease2 trials

Safety and Efficacy of Clenbuterol in Individuals With Late-onset Pompe Disease and Receiving Enzyme Replacement Therapy

Completed·—·Phase 1/2·NCT01942590·17 enrolled

Phase II Clinical Trial of Clenbuterol in Adult Patients With Pompe Disease

Withdrawn·—·Phase 2·NCT04094948

Heart Failure1 trial

Harefield Recovery Protocol Study for Patients With Refractory Chronic Heart Failure

Terminated·FFrancis D. Pagani·Phase 1·NCT00585546·18 enrolled

CLE1 trial

cAMP Signaling and Muscle Adaptations

Unknown status·UUniversity of Copenhagen·N/A·NCT02557581·72 enrolled

Atrophy1 trial

A Placebo-controlled Study of Clenbuterol in Spinal and Bulbar Muscular Atrophy

Recruiting·GGianni Soraru·Phase 2·NCT06169046·90 enrolled

FSHD1 trial

Clenbuterol to Target DUX4 in FSHD

Recruiting·JJeffrey Statland·Phase 1·NCT06721299·30 enrolled

3 more indications

Humans1 trial

Response to Clenbuterol in Humans

Completed·UUniversity of Copenhagen·N/A·NCT03860870·16 enrolled

Amyotrophic Lateral Sclerosis1 trial

Clenbuterol on Motor Function in Individuals With Amyotrophic Lateral Sclerosis

Completed·—·Phase 2·NCT04245709·25 enrolled

Memory1 trial

Muscle Memory After Treatment With Anabolic Substance Clenbuterol and Resistance Training in Humans

Unknown status·MMorten Hostrup, PhD·N/A·NCT05692856·60 enrolled

Sources

References

[1]
ClinicalTrials.gov — 9 trial records for clenbuterol. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — clenbuterol compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for clenbuterol. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University of Copenhagen company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: UUniversity of Copenhagen

clenbuterol

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Q3 2028

Trials by Indication[1]

Pompe Disease2 trials

Heart Failure1 trial

CLE1 trial

Atrophy1 trial

FSHD1 trial

Humans1 trial

Amyotrophic Lateral Sclerosis1 trial

Memory1 trial

References

Drug Info

Quick Facts

Related News